研究目的
To evaluate the effect of preoperative 0.09% bromfenac ophthalmic solution for the reduction of intraoperative miosis and pain in patients who have undergone femtosecond laser-assisted cataract surgery.
研究成果
Topical 0.09% bromfenac is an effective inhibitor of miosis during femtosecond laser-assisted cataract surgery, with greater control of postoperative pain representing an additional significant benefit.
研究不足
Patients were not blinded to the administration of the drug or the placebo, and the study may require a larger sample size to confirm the positive correlation between poor pupillary dilation and greater presentation of intraoperative complications.
1:Experimental Design and Method Selection:
A prospective randomized clinical study was conducted to evaluate the effect of preoperative
2:09% bromfenac ophthalmic solution. Sample Selection and Data Sources:
65 patients with senile cataracts were included, with 60 patients randomized to receive either
3:09% bromfenac or 1% sodium hyaluronate. List of Experimental Equipment and Materials:
Femtosecond laser (LensX System, Alcon Laboratories), SG05 Castroviejo adjustable calliper, Stellaris unit (Bausch and Lomb), Envista foldable monofocal hydrophobic acrylic IOL.
4:Experimental Procedures and Operational Workflow:
Pupil diameter was measured before and after femtosecond laser-assisted cataract surgery. Pain was quantified using a visual analogue scale one day postoperatively.
5:Data Analysis Methods:
Statistical analysis was performed using STATA program (version 15), with Mann-Whitney U test or Student's t-test for continuous variables and c2 test for qualitative variables.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容